There is no corporate or grant support for this activity. This course will fulfill the licensure requirement set forth by the State of Connecticut.

ACCREDITATION
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE
Attending physicians, researchers, house staff, fellows, residents, medical students, nurses.

NEEDS ASSESSMENT
Based on questions raised by pathologists submitting cases in consultation, there are areas of confusion related to the diagnostic criteria used to diagnose myeloid neoplasms.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:
- Understand the rationale for new diagnostic categories of acute myeloid leukemia.
- Be familiar with diagnostic challenges related to myelodysplastic/myeloproliferative neoplasms.
- Understand the relationship between myeloid neoplasms and leukemias of ambiguous lineage.

DESIGNATION STATEMENT
The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES
Speaker Name: Daniel Arber, MD - Monsanto; Jazz Pharmaceuticals; Amgen; Roche
Course Directors: Manju Prasad, MD - NONE
Kurt Schalper, MD, PhD - NONE
Gopal Pallavi, MD, PhD - NONE
It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months, and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.

NEEDS ASSESSMENT
Based on questions raised by pathologists submitting cases in consultation, most pathologists have little exposure to spleen specimen and the unique tumors that involve them.

LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:
- Be familiar with the vascular proliferations unique to the spleen.
- Differentiate the lymphomas that typically are primary to the spleen from secondary involvement.
- Understand the diagnostic criteria for stromal proliferations unique to the spleen.

DIAGNOSTIC SLIDE SEMINAR

GRAND ROUNDS AND DIAGNOSTIC SLIDE SEMINAR
Host: Mina Xu, MD

DIAGNOSTIC SLIDE SEMINAR: 8:30 AM
“Splenic Tumors”

GRAND ROUNDS: 12:30 PM
“Update on the Pathology of Myeloid Neoplasms”

Thursday, October 29, 2020
Zoom Meetings ID and Password: emailed separately
For information contact: susana.cruz@yale.edu

There is no corporate or grant support for this activity. This course will fulfill the licensure requirement set forth by the State of Connecticut.